Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL13Ralpha2-Targeted CAR T Cells for Children With Recurrent/Refractory Malignant Brain Tumors
NCT04510051Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2020
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells in malignant brain neoplasm, sponsored by City of Hope. Primary endpoint: Incidence of adverse events. Started Dec 2020; status: recruiting.
02
Drugs
IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells
03
Conditions
malignant brain neoplasm
Beyond the preview
Go deeper on NCT04510051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510051.